Estrogen adversely affects the prognosis of patients with lung adenocarcinoma

Li-Han Hsu,1,2 Ko-Jiunn Liu,3 Ming-Fang Tsai,4,5 Chang-Ru Wu,5 An-Chen Feng,6 Nei-Min Chu7 and Shu-Huei Kao5

1Division of Pulmonary and Critical Care Medicine, Sun Yat-Sen Cancer Center, Taipei; 2Department of Medicine, National Yang-Ming University Medical School, Taipei; 3National Institute of Cancer Research, National Health Research Institutes, Zhunan, Miaoli County; 4Graduate Institute of Medical Science, College of Medicine, Taipei Medical University, Taipei; 5School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei; 6 Departments of Research; 7 Medical Oncology, Sun Yat-Sen Cancer Center, Taipei, Taiwan

Key words
Epidermal growth factor receptor, estrogen, estrogen receptor, lung cancer, osteopontin

Correspondence
Shu-Huei Kao, School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan.
Tel: +886 2 2736-1661 ext. 3317; Fax: +886 2 2732-4510; E-mail: kaosh@tmu.edu.tw

Funding information
None declared.

Received May 22, 2014; Revised October 4, 2014; Accepted October 10, 2014

Cancer Sci 106 (2015) 51–59
doi: 10.1111/cas.12558

Estrogen is thought to play an important role in lung cancer carcinogenesis.1,2 Estrogen has also been reported to adversely affect the prognosis of patients with lung cancer.3–9 However, there are also some study results that are contradictory to this.10–14 We previously examined gender-associated differences in non-small cell lung cancer (NSCLC) and noted that elderly women with lung adenocarcinoma had a more significant survival advantage than their male counterparts.15 In addition to the cumulative adverse effects of smoking in the elderly male patients, the longer survival of the postmenopausal female patients may also have been due to a lower estrogen cancer-promoting effect. With more patients recruited and extended follow up, we re-examined the evidence and a comparison was made between premenopausal and postmenopausal female never-smoking adenocarcinoma patients.

Drugs targeting the estrogen signaling pathway have been shown to suppress the growth of lung cancer cells.4,16,17 To examine the role of estrogen, the expression of estrogen receptor (ER) in lung cancer cells, the effect of estrogen on cancer cell migration and the relationship between estrogen and osteopontin (OPN) were investigated. The individual and combined effect of ER antagonists and epidermal growth factor receptor (EGFR) antagonists on cancer cell migration was also studied.

Materials and Methods

Epidemiology study design and patients. Consecutive NSCLC patients were prospectively enrolled in an electronic database called the Cancer Information System at the Sun Yat-Sen Cancer Center from January 2002 to December 2008, and followed until December 2012. They were clinically and pathologically staged and underwent homogenous treatment algorithms, as described previously.15 The possible prognostic factors to be analyzed included stage, age, gender, menopausal status, smoking history and histology. For laboratory study, lung cancer cell lines A549 and PE089 and malignant pleural effusions from the patients with lung adenocarcinoma were used. We found that the premenopausal patients had more advanced disease and a shorter survival among the never-smoking female patients with lung adenocarcinoma. ERβ was the predominant ER in the lung cancer cell lines. We proposed a different pathway that estrogen upregulated the expression of osteopontin and then promoted cell migration through αvβ3 integrin binding and activated MEK-ERK signaling pathway, which is a common downstream pathway with epidermal growth factor receptor (EGFR) activation. An additive effect of ER antagonists and EGFR antagonists on the inhibition of cell migration was also noted. Our results suggest that estrogen adversely affects the prognosis of patients with lung adenocarcinoma. Osteopontin contributed to the cross-talk between ER and EGFR signaling pathways. Estrogen, with its receptor, has the potential to be a prognosticator and a therapeutic target in lung cancer.
December 2011 at the Sun Yat-Sen Cancer Center. Another 25 female patients (age 66.7 ± 12.6 years) with non-malignant pleural effusion were included as controls. The etiologies include indeterminate lymphocytic exudate, predominant exudate (n = 14), transudates secondary to liver cirrhosis or metastasis (n = 4), para-pneumonia (n = 3), heart failure (n = 2), and surgery or radiotherapy (n = 2). All of the pleural effusions were centrifuged at 3000 g for 10 min and fresh frozen at −80°C. The Institutional Review Board of the hospital approved this study as well as the database used to collect the data. All the patients of the cohort for epidemiology study and the subgroup involved in the laboratory study provided written informed consent before study entry. The study was also approved by the local Ethics Committee and was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the guidelines on good clinical practice.

**Chemicals.** The drugs and chemicals used in this study were purchased from different companies: 17β-estradiol (E2), diarylpropionitrile (DPN), EGF (Addgene, Cambridge, MA, USA), shRNA targeting ERβ (with an oligonucleotide sequence of 5’-CTTTAATCTCCTTCCTCCA-T3’; Academia Sinica, Taipei, Taiwan), pcDNA3.1 (scramble shRNA) or siOPN (Ambion Silencer) using Lipofectamine TM 2000 (Invitrogen, Carlsbad, CA, USA). Cells transfected with the plasmids were selected by 400 μg/mL G418 for 4 weeks.

**Plasmid transfection.** Serum-starved cells were transfected with pRST-ESR2 (ERβ) (Addgene, Cambridge, MA, USA), shRNA targeting ERβ (with an oligonucleotide sequence of 5’-CTTTAATCTCCTTCCTCCA-T3’; Academia Sinica, Taipei, Taiwan), pcDNA3.1 (scramble shRNA) or siOPN (Ambion Silencer) using Lipofectamine TM 2000 (Invitrogen, Carlsbad, CA, USA). Cells transfected with the plasmids were selected by 400 μg/mL G418 for 4 weeks.

**Estradiol measurements.** The E2 levels in pleural effusions were measured with an ARCHITECT E2 assay (Estradiol Reagent Kit 7K72; Abbott Labs, Abbott Park, IL, USA). The results were expressed as picograms per milliliter for E2.

**Enzyme-linked immunosorbent assay for osteopontin.** A Human Osteopontin TiterZyme Enzyme Immunoassay (ELIA) kit (Genentech, Branchburg, NJ, USA) and anti-OPN (AKm2A1; Santa Cruz Biotechnology, Santa Cruz, CA, USA) were purchased from different companies. Cells transfected with the plasmids were selected by 400 μg/mL G418 for 4 weeks.

**Cell lines.** A549 and MCF-7 cell lines were purchased from ATCC (Manassas, VA, USA). The PE089 was characterized as harboring an EGFR exon 19 deletion and derived from a female patient with adenocarcinoma of the lung (courtesy of K. J. Liu from the National Health Research Institute). Both cell lines were maintained in phenol-red free DMEM and nutrient mixture (20%) supplemented with 5% heat-inactivated and dextran-coated-charcoal-stripped FBS (Life Technologies, Gaithersburg, MD, USA).

**Western blot analysis.** Equal amounts of protein were electrophoresed on 8% SDS-PAGE, then transferred to PVDF membranes (GE Healthcare Bioscience, Fribourg, Switzerland) and immunoblotted. The following primary antibodies were used for immunohistochemistry: anti-ERα (HC20), anti-ERβ (H-150), anti-p-ERK (E4), anti-OPN (AKm2A1; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-ERK1/2 (E31R; GeneTex, Irvine, CA, USA) and anti-GAPDH (#4300; Ambion Silencer, Carlsbad, CA, USA) were purchased from different companies: 17β-estradiol (E2), diarylpropionitrile (DPN), EGF (Addgene, Cambridge, MA, USA), shRNA targeting ERβ (with an oligonucleotide sequence of 5’-CTTTAATCTCCTTCCTCCA-T3’; Academia Sinica, Taipei, Taiwan), pcDNA3.1 (scramble shRNA) or siOPN (Ambion Silencer) using Lipofectamine TM 2000 (Invitrogen, Carlsbad, CA, USA). Cells transfected with the plasmids were selected by 400 μg/mL G418 for 4 weeks.

**Statistical analysis.** For epidemiological results, the Pearson χ²-test was used to evaluate the associations between stage, smoking history, gender and histology. The Wilcoxon rank-sum test was used to test differences in median age. Kaplan–Meier plots and the log-rank test were used to assess the association of groups with survival. Multivariate analysis of overall survival was performed according to the Cox proportional hazards model using the clinical prognostic factors. Laboratory data were presented as mean ± standard deviation. The results of different experimental treatments were analyzed using Student’s t-tests. A two-sided P-value of <0.05 was considered to be significant. Analysis was performed using the statistical software package SAS, version 9.1.3 (SAS Institute, Cary, NC, USA).

**Results**

**Epidemiology study. Patient characteristics.** A total of 1434 NSCLC patients (668 women) were enrolled in the study. The

| Variable | Women (n = 668) | Men (n = 766) | P-value |
|----------|----------------|--------------|---------|
| Median age, years | 59 | 64 | <0.001 |
| History of smoking (%) | 42 (7) | 574 (75) | <0.001 |
| Smoker (%) | Adenocarcinoma | 31 (91) | 307 (68) | 0.005 |
| Squamous cell carcinoma | 3 (9) | 145 (32) | |
| Never-smoker (%) | Adenocarcinoma | 511 (95) | 149 (94) | 0.80 |
| Squamous cell carcinoma | 28 (5) | 9 (6) | |
| Stage of NSCLC (%) | | | |
| I | 86 (13) | 86 (11) | 0.18 |
| II | 25 (4) | 37 (5) | |
| III | 186 (28) | 246 (32) | |
| IV | 371 (56) | 397 (52) | |

NSCLC, non-small cell lung cancer.
Patient characteristics are shown in Table 1. The female patients were younger and a higher percentage of female patients had adenocarcinomas. Seventy-five percent of the male patients and 7% of female patients had smoking history.

**Survival analysis.** In the patients with lung adenocarcinoma, multivariate analysis indicated that stage (hazard ratio [HR], 2.13; \( P < 0.01 \)), age (HR, 1.36; \( P < 0.01 \)) and smoking history (HR, 1.08; \( P < 0.01 \)) were independent prognostic factors. Gender did not reach statistical significance (HR, 1.38; \( P = 0.41 \)). The never-smokers had a longer survival than the smokers (median survival: 695 vs 493 days; \( P < 0.01 \)) (Fig. 1a). The survival was similar between never-smoking women and men (median survival: 715 vs 677 days; \( P = 0.39 \)) (Fig. 1b).

Compared with the male patients, the survival superiority of the female patients with lung adenocarcinoma appeared to be more significant in the elderly group (Fig. 1c–e). Among the never-smoking female patients with lung adenocarcinoma, the premenopausal women had a shorter survival than the postmenopausal women (median survival: 643 vs 735 days; \( P = 0.01 \)) (Fig. 1f). The multivariate analysis including stage, age and menopausal status showed that stage was the only independent prognostic factor (HR, 2.15; \( P < 0.01 \)). Premenopausal women had more advanced disease (stage I 8%, stage...
II 5%, stage III 21% and stage IV 66%) than the postmenopausal women (stage I 16%, stage II 4%, stage III 27% and stage IV 53%; P = 0.04).

**Laboratory study.** Estrogen promoted cell migration via ERβ activation of the MEK/ERK signaling pathway. For quantification of the wound healing, the wound area of nontreated cells for 24 h is defined as 100%. Wound healing assays of A549 or PE089 cells incubated with E2 showed a significant decrease in wound area. The PE089 cells showed a higher migratory ability than the A549 cells in the presence of E2. Tamoxifen significantly reduced the E2-induced cell migration in A549 and PE089 cells (Fig. 2a,b).

To identify whether the molecular signals controlled E2-mediated cell migration through the MEK/ERK pathway, A549 cells and PE089 cells were subjected to wound healing assays in the presence of E2 and/or U0126 for 24 h. U0126 significantly decreased the E2-induced cell migration (Fig. 2c), and reduced the E2-induced phosphorylation of ERK (p-ERK, Fig. 2d). These results indicated that the estrogen-induced cell migration was via activation of the MEK/ERK signaling pathway, which is also a downstream pathway of EGFR activation.

Western blot analysis revealed that ERβ was the predominant receptor expressed in the lung cancer cell lines (Fig. 2e). To further investigate the effects of ERβ, we established two cell clones: one with pRST-ESR2 overexpressing ERβ (ERβ O/E), and the other transfected with ERβ shRNA (ERβ knockdown) (Fig. 2f). A 1.5-fold increase in growth rate was found in the ERβ O/E cell clone with E2 stimulation for 24 h (Fig. 2g). DPN (ERβ agonist) treatment stimulated cell migration in a similar fashion to E2. ERβ knockdown with shRNA, tamoxifen and ICI 182780 (ICI) resulted in a significant reduction of cell migration (Fig. 2h).

![Fig. 2. Estrogen promoted cell migration via estrogen receptor β (ERβ) activation of the MEK/ERK signaling pathway.](image-url)

(a) A549 cells and PE089 were subjected to wound healing assays for 24 h in the presence of 100 nM estradiol (E2), 10 μM tamoxifen citrate (T, ER antagonist), co-treatment with E2 and tamoxifen citrate (E2 + T), or ethanol equivalent as the control. (b) The wound area of A549 or PE089 cell migration was analyzed. The lines indicate the boundary of the edges of the wound after 24 h. The bars represent mean ± standard deviation relative to the cells treated with ethanol. (c) A549 and PE089 cells were cultured in the presence of E2 and/or U0126 (U, MEK inhibitor) for 24 h, U0126 reduced E2-induced cell migration. (d) Western blotting of the ERK and phosphorylated ERK of the cells treated with E2 and/or U0126 showed estrogen-induced ERK phosphorylation was inhibited by U0126. (e) Western blotting showed that ERβ was the predominant receptor type in the lung cancer cell lines. (f) Transfection of the A549 cells with the human ERβ gene or ERβ shRNA was performed to establish an ERβ overexpression cell clone (ERβ O/E) and ERβ depletion cell clone (shRNA), respectively. (g) ERβ O/E with E2 stimulation resulted in a maximal increase in cell growth rate. (h) The migratory ability of the various indicated cells was analyzed. DPN (ERβ agonist) and E2 induced migration of ERβ O/E cell. ER inhibitor (ICI 182780, ICI), tamoxifen and ERβ knockdown with shRNA resulted in a reduction of cell migration. *P < 0.05; **P < 0.01 compared with the control; #P < 0.05; ##P < 0.01 compared with the E2 group. Cv, control vector; O/E, overexpression.
Additive effect of estrogen receptor antagonist (tamoxifen) and epidermal growth factor receptor antagonist (gefitinib) on the inhibition of lung cancer cell migration. The effects of E2 and EGF on cancer cell migration were then compared, and the highest stimulation of cell migration was observed when both E2 and EGF were present in the culture (EE group in Fig. 3a). A significant difference in the wound healing assay was found between EE + TG and EE + G (P < 0.05, Fig. 3a). Up to a 3.3- and 2.6-fold increase of p-ERK were found in the EE group of PE089 cell line and A549 cell line, respectively (Fig. 3b). The E2 and EGF induced ERK phosphorylation was downregulated in the presence of tamoxifen and/or gefitinib. Tamoxifen and gefitinib together acted in an additive manner to inhibit E2 and EGF induced cell migration and ERK phosphorylation (Fig. 3a,c).

Estrogen induced osteopontin expression. To test whether OPN was a downstream molecule of the estrogen signaling pathway and whether it contributed to cell migration, the expression levels of the OPN gene were quantified. A 2.2-fold increase in OPN mRNA level was detected in the E2-treated A549 cells (Fig. 4a,b). The protein levels of OPN also increased in the medium cultured with E2 (Fig. 4c). Both the E2-induced OPN expressions were reduced in the presence of tamoxifen (Fig. 4a–c). OPN-induced cell migration and ERK phosphorylation were significantly inhibited by U0126 (MAP kinase/MEK inhibitor) (Fig. 4d,e). The integrin receptor αvβ3 interacts with OPN via the arginine-glycine-aspartate (RGD) motif. The anti-αvβ3 Ab significantly inhibited OPN-induced cell migration and E2-stimulated or EGF-stimulated cell migration (Fig. 4f). These results suggested that estrogen induced OPN expression and promoted cancer cell migration through αvβ3 integrin binding and MEK/ERK signaling, and implied that OPN–αvβ3 integrin-induced cell migration was involved in the activation of ER and EGFR signaling pathways.

Estradiol and osteopontin both elevated and positively correlated in the malignant pleural effusions from patients with lung adenocarcinoma. To investigate whether the cell-free supernatants of malignant pleural effusions provide a migratory niche for A549 or PE089 cells, the cells were incubated with the malignant pleural effusions from patients with lung adenocarcinoma (n = 24). In Figure 5(a), the wound healing assays were treated with the malignant pleural effusion from a female never-smoker patient with lung adenocarcinoma harboring an EGFR exon 21 L858R mutation. We found that the malignant pleural effusions more intensely promoted cell migration than E2 or EGF. Additive inhibition of the malignant pleural effusion-induced cell migration was found with tamoxifen and gefitinib supplementations (Fig. 5a,b). Patients with malignant pleural effusion had higher pleural fluid E2 (median, 13.0 vs 10.0 pg/mL; P = 0.085) and OPN (median, 318.77 vs 256.28 ng/mL; P = 0.289) concentrations than those with non-malignant pleural effusion, although statistical significance was not achieved.
was not reached. The premenopausal women had higher pleural fluid E2 (median, 21.5 vs 13.0 pg/mL; \( P = 0.044 \)) concentrations than the postmenopausal women. Pleural fluid E2 and OPN concentrations were positively correlated (\( n = 62, r = 0.74, P = 0.002 \); Fig. 5c).

**Discussion**

There is a lung adenocarcinoma epidemic in Taiwanese women who have never smoked.\(^{18}\) In addition to the role of cooking fumes and passive smoking frequently discussed, estrogen is speculated to play an important role in lung cancer carcinogenesis and to adversely affect patients’ prognosis. In the study, smoking history remained a poor prognostic factor for patients with lung adenocarcinoma. Never-smoking women and men with lung adenocarcinoma had similar survival rates. An estrogen cancer-promoting effect appears to be responsible for the more advanced disease in the premenopausal female never-smoking adenocarcinoma patients and contributes to a shorter survival, in spite of more comorbidities existing in the postmenopausal women.

Estrogen receptors are consistently found in lung cancer tissues and lung cancer cell lines (especially adenocarcinoma), mostly in the form of ER\( \beta \).\(^{19-22}\) In addition to cell proliferation, cell migration and degradation of the extracellular matrix are crucial steps in tumor progression. In the study, we demonstrated that cancer cell migration could be stimulated by E2 \(^{23,24}\) and that an ER antagonist inhibited this effect. Through establishing cell clones with ER\( \beta \) overexpression or knockdown and the application of an ER\( \beta \)-specific agonist or antagonist, we demonstrated that estrogen promotes cell migration via ER\( \beta \).

Recent research has elucidated the pivotal role of OPN, a small integrin-binding ligand N-linked glycoprotein in regulating the cell signaling that controls tumor progression and metastasis.\(^{23,24}\) Enhanced OPN expression has been noted in the plasma of advanced lung cancer patients, and OPN has also been speculated to be involved in the formation of malignant pleural effusions.\(^{25-29}\) Estrogen-related receptors (ERR) have been known to regulate the synthesis of osteopontin and ERRalpha response elements have been identified in the OPN promoter.\(^{30,31}\) Estrogen was demonstrated to regulate OPN expression and lead to angiogenesis and metastasis in breast cancer.\(^{32}\) Our results demonstrated that E2 can augment OPN expression and secretion and induce cell migration through \( \alpha v \beta 3 \) integrin binding in lung adenocarcinoma. The elevated and positively correlated pleural fluid E2 and OPN
concentrations in patients with lung adenocarcinoma supported the in vitro findings.

For the elevated pleural fluid E2 concentrations in malignant pleural effusion, we measured the pleural fluid vascular endothelial growth factor (VEGF) and urokinase-type plasminogen activator concentrations in a subsequent study of the same population. Although patients with malignant pleural effusion had higher VEGF than those with non-malignant pleural effusion (median, 1028.82 vs 462.85 pg/mL; \( P=0.022 \)), there was no significant correlation between pleural fluid E2 and VEGF concentrations, which is a marker of pleural vascular hyperpermeability (unpublished data by Hsu LH, Hsu PC, Liao TL, Feng AC, Chu NM and Kao SH). Increased pleural permeability is the predominant mechanism of malignant pleural fluid formation, but we could not attribute the elevated pleural fluid E2 concentration to the increased E2 permeation into pleural cavity. However, we also observed that some postmenopausal women had extraordinary high pleural fluid E2 concentrations. Studies with bigger case numbers are needed to determine whether increased production of E2 or increased E2 permeation into pleural cavity contributed to the higher pleural fluid E2 concentration in malignant pleural effusion.

Patients with lung adenocarcinoma have specific mutations in the EGFR gene which lead to the activation of growth factor signaling and conferring susceptibility to tyrosine kinase inhibitors.\(^{(32-35)}\) Treatment of tumor cells in vitro or in nude mice with lung tumor xenografts in vivo with inhibitors of aromatase, an estrogen synthase, has been shown to lead to significant suppression of tumor growth.\(^{(4,16,17)}\) In addition, a combination of ER antagonists and EGFR-tyrosine kinase inhibitors has been shown to decrease cell proliferation and tumor growth more than one individual treatment in both in vitro and in vivo studies.\(^{(17,36-38)}\) Stabile et al.\(^{(36)}\) found that EGFR protein expression was downregulated in response to estrogen and upregulated in response to anti-estrogens in vitro. Conversely, ER\(\beta\) expression was found to be decreased in response to EGF and increased in response to gefitinib. A strong association has been reported between the expression of ER\(\beta\) and EGFR mutations in adenocarcinoma of the lung.\(^{(39,40)}\) These studies provide evidence of a functional interaction between the ER and EGFR pathways in lung cancer and support a rationale to use combined therapy.\(^{(41,42)}\) In the study, treatment with U0126, an MEK inhibitor, attenuated the cancer cell migration stimulated by E2 and OPN, implicating their
actions through the MEK-ERK signaling pathway, which is also a downstream signaling pathway after activation of EGFR and possibly contributes to the crosstalk among E2, OPN and EGFR (Fig. 5d). The combination of estrogen and EGFR resulted in maximal stimulation of cell migration and ERK phosphorylation. Conversely, the combination of tamoxifen and gefitinib resulted in maximal inhibition of these effects.

We used a large, prospective cohort epidemiologic study and controlled for the confounding effect of smoking to evaluate the role of estrogen. However, there are potential limitations. We were not able to include hormone replacement therapy in the analysis. However, the biological plausibility was still generalized when compared to the relatively short-term effect of hormone replacement therapy with the survival trend over a long period. Analysis of its use was also subject to recall bias. For laboratory evidence, whether or not differences exist in the data endpoints in relation to EGFR mutation status should be confirmed in more than one cell line of each type to make any conclusions.

In summary, we proposed a different pathway of ER activation and interaction with EGFR (Fig. 5d). Estrogen, with its receptor, has the potential to be a prognosticator and a therapeutic target in lung cancer. ER antagonist may become a new effective treatment modality for patients with lung adenocarcinoma and an alternative treatment for patients with acquired resistance to EGFR antagonists. Considering the conflicting results in the literature, further clinical research and laboratory experiments should be undertaken to clarify the interaction of estrogen with various mediators and to elucidate its role in carcinogenesis, cell proliferation, migration and invasion.

Acknowledgment

The authors thank Miss Yun-Ying Chen for preparation of the figures and graphics.

Disclosure Statement

The authors have no conflict of interest to declare.

References

1. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996; 88: 183–92.
2. Siegfried JM. Women and lung cancer: does oestrogen play a role? Lancet Oncol 2001; 2: 506–13.
3. Omoto Y, Kobayashi Y, Nishida K et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 2001; 285: 340–7.
4. Stabile LP, Davis AL, Gubish CT et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 2002; 62: 2141–50.
5. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006; 24: 59–63.
6. Niikawa H, Suzuki T, Miki Y et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 2008; 14: 4417–26.
7. Zhang G, Yanamala N, Lathrop KL, Zhang L, Klein-Seetharaman J, Srinivas H. Ligand-independent antiapoptotic function of estrogen receptor-β in lung cancer cells. Mol Endocrinol 2010; 24: 1737–47.
8. Mah V, Marquez D, Alavi M et al. Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer. Lung Cancer 2011; 74: 319–25.
9. Chlebowski RT, Schwartz AG, Wakelee H et al. Oestrogen plus progesterin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009; 374: 1243–51.
10. Schwartz AG, Wenzlaff AS, Pysak GM et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non-small-cell lung cancer in women. J Clin Oncol 2007; 25: 5785–92.
11. Chen KY, Hsiao CF, Chang GC et al. Hormone replacement therapy and lung cancer risk in Chinese. Cancer 2007; 110: 1768–75.
12. Huang B, Carlos H, Wyatt SW, Riley E. Hormone replacement therapy and survival in lung cancer in postmenopausal women in a rural population. Cancer 2009; 115: 4167–72.
13. Ayeni O, Robinson A. Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed? Cancer 2009; 116: 21–5.
14. Chlebowski RT, Anderson GL, Manson JE et al. Lung cancer among postmenopausal women treated with estrogen alone in the Women’s Health Initiative randomized trial. J Natl Cancer Inst 2010; 102: 1431–23.
15. Hsu LH, Chen ML, Liu CC et al. Sex-associated differences in non-small cell lung cancer in the new era: is gender an independent prognostic factor? Lung Cancer 2009; 66: 262–7.
16. Weinberg OK, Marquez-Garban DC, Fishbein MC et al. Aromatase inhibitors in human lung cancer therapy. Cancer Res 2005; 65: 11287–91.
17. Marquez-Garban DC, Chen HW, Goodglick L, Fishbein MC, Petras RJ. Tamoxifen and estrogen signaling in human non-small cell lung cancer. Ann N Y Acad Sci 2009; 1155: 194–205.
18. Health Promotion Administration, Ministry of Health and Welfare, The Executive Yuan, Taiwan. Cancer registry annual report, 2011. [Cited April 16 2014.] Available from URL: http://www.hpa.gov.tw.
19. Zhang G, Liu X, Farkas AM et al. Estrogen receptor β functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol 2009; 23: 146–56.
20. Stabile L, Siegfried J. Estrogen receptor pathways in lung cancer. Curr Oncol Rep 2004; 6: 259–67.
21. Kawaji H, Ishii A, Wakiya K et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005; 11: 5084–9.
22. Schwartz AG, Pysak G, Murphy V et al. Nuclear estrogen receptor β in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005; 11: 7290–7.
23. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006; 16: 79–87.
24. Bellahcene A, Castronovo V, Ogubreke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked glycoproteins (SIBLINGS): multifunctional proteins in cancer. Nat Rev Cancer 2008; 8: 212–26.
25. Cui R, Takahashi F, Ohashi R et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer 2009; 63: 368–74.
26. Mack PC, Redman MW, Chansky K et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003. J Clin Oncol 2008; 26: 4771–6.
27. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007; 57: 373–80.
28. Isa SI, Kawaguchi T, Teramukai S et al. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer. J Thorac Oncol 2009; 4: 1104–10.
29. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of elevated plasma osteopontin levels with resection of non-small cell lung cancer. J Clin Oncol 2010; 28: 936–41.
30. Zirngibl RA, Chan JS, Aubin JE. Divergent regulation of the osteopontin promoter by the estrogen receptor-related receptors is isoform- and cell context dependent. J Cell Biochem 2013; 114: 2356–62.
31. Zirngibl RA, Chan JS, Aubin JE. Estrogen receptor-related receptor alpha (ERRalpha) regulates osteopontin expression through a non-canonical ERRalpha response element in a cell context-dependent manner. J Mol Endocrinol 2008; 40: 61–73.
32. de Silva Rudland S, Martin L, Rooshanall C et al. Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. Clin Cancer Res 2006; 12: 1192–200.
33. Pazc GJ, Jänne PA, Lee JC et al. EGFR mutations in lung cancer – correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–500.
34. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–39.
35 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–57.
36 Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005; 65: 1459–70.
37 Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005; 70: 372–81.
38 Marquez-Garbán DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ. Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 2007; 72: 135–43.
39 Nose N, Sugio K, Oyama T et al. Association between estrogen receptor-β expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2008; 27: 411–7.
40 Raso MG, Behrens C, Herynk MH et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009; 15: 5359–68.
41 Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003; 17: 309–17.
42 Dubey S, Siegfried JM, Traynor AM. Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol 2006; 7: 416–24.
43 Giovannini M, Belli C, Villa E, Gregorc V. Estrogen receptor and epidermal growth factor receptor as targets for dual lung cancer therapy: not just a case? J Thorac Oncol 2008; 3: 684–5.
44 Garon EB, Pietras RJ, Finn RS et al. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer. J Thorac Oncol 2013; 8: 270–8.
45 Patel JD, Gray RG, Stewart JA, Skinner HG, Schiller JH. Tamoxifen does not reduce the risk of lung cancer in women. J Clin Oncol 2005; 23: s7212.